Methylene blue injectable in combination with serotonin reuptake inhibitors – Association with serotonin toxicity – Notice to Hospitals (2011)

Government Record · Health Canada (Health Products and Food Branch, Marketed Health Products Directorate) · February 16, 2011

Health Canada's 16 February 2011 Notice to Hospitals warned that intravenous methylene blue given to patients on serotonin reuptake inhibitors has caused serotonin toxicity, including at 1 mg/kg, and told hospitals to consider a washout of at least 4-5 half-lives. It says Health Canada would work with market authorisation holders to add these points to Canadian prescribing information.

Serotonin toxicity has been reported when methylene blue was administered intravenously at concentrations as low as 1 mg/kg, in patients receiving selective serotonin reuptake inhibitors (SSRIs) or other drugs with serotonin reuptake inhibition properties (e.g., duloxetine, venlafaxine and clomipramine).

Health Canada's 16 February 2011 Notice to Hospitals warned that intravenous methylene blue given to patients on serotonin reuptake inhibitors has caused serotonin toxicity, including at 1 mg/kg, and told hospitals to consider a washout of at least 4-5 half-lives. It says Health Canada would work with market authorisation holders to add these points to Canadian prescribing information. C1 and C2. Read from the Internet Archive capture; the original hc-sc.gc.ca path no longer serves the document on the modern canada.ca site (no capture found for the canada.ca equivalent, which could not be opened from this machine). IMPORTANT for C2: this notice is NOT limited to parathyroid/surgical use – it speaks of intravenous methylene blue generally and gives 1 mg/kg as the lowest reported dose. A PDF version ("PDF Version – 39 K") is linked on the page but was not retrieved. Foreign Government copyright status per rule; government notice, reproduced as a quotation for record purposes. Also filed as MTO-14 (claims C1, C2). Study type: regulatory record.